EGFR and non-small cell lung carcinoma: NSCLC has become recognized as being a heterogeneous set of diseases (Reck et al., 2013) and, in patients with lung adenocarcinomas, epidermal growth factor receptor (EGFR) mutations are associated with response to EGFR inhibitors.